Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Therapies
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 23 octobre 2019
Doi : 10.1016/j.therap.2019.09.003
Received : 20 June 2019 ;  accepted : 16 September 2019
Éléments de l’interprétation et du dialogue clinico-biologique pour le suivi thérapeutique pharmacologique de la vancomycine
Practical information for therapeutic drug monitoring of vancomycine
 

Sandrine Lefeuvre a, , Julie Bois-Maublanc a, Romain Guilhaumou b
pour le

groupe Suivi thérapeutique pharmacologique et personnalisation des traitements de la Société française de pharmacologie et thérapeutique

a Laboratoire de biochimie-pharmacologie-toxicologie, CHR La Source, 14, avenue de l’Hôpital, 45067 Orléans, France 
b Service de pharmacologie clinique et pharmacovigilance, hôpital de la Timone, CHU de Marseille, 13000 Marseille, France 

Auteur correspondant.

Keywords : Vancomycin, Therapeutic drug monitoring

Mots clés : Vancomycine, Suivi thérapeutique pharmacologique




© 2019  Société française de pharmacologie et de thérapeutique@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline